Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

  • This share is currently suspended. It was suspended at a price of 7.23
  • There is currently no data for TRX

AGM Statement

25 May 2006 07:04

Torex Retail PLC25 May 2006 25 May 2006 Torex Retail Plc AGM STATEMENT Torex Retail ("Torex Retail" or "the Group"), an international market leader inthe provision of innovative retail IT systems, will today hold its AnnualGeneral Meeting. Chris Moore, Chairman and Chief Executive, will make thefollowing statement on current trading: The Group has made a good start to the year enjoying sales success in all ourkey business areas and geographic markets. In addition to the £30 million of newcontracts that we secured in the first quarter, the Group has continued to winsignificant contracts with new and existing customers including McDonald's,Boots, Liz Claiborne, BT, Tesco, Walmart-Asda and the Dutch Post Office. Particularly pleasing was a contract with The Picture People, a US portraitstudio chain with over 300 outlets nationwide. This was our first new businesswin for our Lucas EPoS product from a US headquartered retailer and was achievedwithin a year of the launch of this product into the US market. The system willstart roll out in July and will be a valuable reference site for further salesprogress in the US. Integration of 2005 acquisitions has continued to plan and we have now agreedformal employment plans with our employees in Germany. As a result, plans arenow being implemented to reduce the workforce by approximately 150 employees,with restructuring costs and subsequent annualised savings in line with theoriginal estimates previously communicated to the Stock Market. In April we completed the US$55 million acquisition of Savista, whichrepresented a major strategic step in the development of our Group and itsfurther penetration of the US market. Torex Retail is now the global EPoSsupplier to McDonalds and a market leader in the Quick Service Restaurantsector, the fastest growing part of the hospitality market. We see tremendousopportunities for this business going forward both from increased sales toMcDonalds and new business wins from other international QSR chains and alsothrough indirect channel sales. Trading for the first quarter was in line with our budget and the continuedlevel of order intake gives the Board confidence that the first six months of2006 will meet expectations. As in previous years, we expect trading activity toincrease in the second six months of 2006. Based on our current order book andsales pipeline, we are confident of achieving the full year forecastexpectations currently in the Stock Market. Chris Moore, Chairman and Chief Executive of Torex Retail, commented: "I am delighted with the progress we have made this year to date. The continuingprogramme of integrating our acquisitions is delivering bottom line savings andoperating efficiencies at the same time as we continue to target top linegrowth. Last year saw us become the leading provider of retail IT systems across Europeand we believe 2006 will see us make significant steps towards becoming aleading supplier to the North American market as well as further strengtheningour market position and brand on the global stage. The continuing delivery of the company strategy is both exciting and representsfurther consolidation of delivering shareholder value". - ends - For further information please contact: Torex RetailChris Moore, Chairman and Chief Executive +44 (0)870 300 6061 Citigate Dewe RogersonGinny Pulbrook, Executive Director +44 (0)20 7282 2945Seb Hoyle, Associate Director +44 (0)20 7282 2822 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
13th Nov 20249:32 amRNSForm 8.3 - Tissue Regenix Group Plc
12th Nov 20244:05 pmRNSForm 8 (OPD) (Tissue Regenix Group Plc)
12th Nov 20248:46 amRNSForm 8.5 (EPT/NON-RI)
11th Nov 20249:17 amRNSForm 8.5 (EPT/NON-RI)
7th Nov 20249:59 amRNSForm 8.5 (EPT/NON-RI) - Tissue Regenix Group PLC
6th Nov 20241:37 pmRNSForm 8.3 - Tissue Regenix Group PLC
6th Nov 20248:52 amRNSForm 8.5 (EPT/NON-RI)
5th Nov 20242:24 pmRNSForm 8.3 - Tissue Regenix Group PLC
5th Nov 202411:32 amRNSForm 8.5 (EPT/NON-RI)
4th Nov 20244:36 pmRNSResponse to media speculation
10th Sep 20247:00 amRNSInterim results for the six months ended 30 June
18th Jul 20243:52 pmRNSGrant of share options
16th Jul 20247:00 amRNSHalf-Year Trading Update
3rd Jul 20241:16 pmRNSHolding(s) in Company
24th Jun 20244:12 pmRNSHolding(s) in Company
18th Jun 20245:15 pmRNSExercise of Options, Director Dealing and TVR
14th Jun 20247:00 amRNSBuilding purchase
25th Apr 20242:27 pmRNSResult of AGM
10th Apr 20247:15 amEQSHardman & Co Research on Tissue Regenix (TRX): Six consecutive periods of >20% growth
5th Apr 20243:52 pmRNSHolding(s) in Company
19th Mar 20247:00 amRNSFinal results for the year ended 31 December 2023
1st Mar 20247:00 amRNSNotice of Results
6th Feb 20247:00 amRNSFirst EU shipment & new distributor agreements
29th Jan 20243:02 pmRNSHolding(s) in Company
25th Jan 20247:00 amRNSTrading update for 2023
23rd Jan 20245:24 pmRNS2023 LTIP Grant
22nd Nov 20234:36 pmRNSHolding(s) in Company
30th Oct 20237:00 amRNSHPRA approval & distribution agreement in Spain
18th Sep 202310:40 amEQSHardman & Co Research on Tissue Regenix (TRX): Continuing postive momentum 1H'23
15th Sep 20234:30 pmRNSDirector/PDMR Shareholding
5th Sep 20237:01 amRNSNew sports medicine product launch
5th Sep 20237:00 amRNSInterim results
31st Aug 20231:45 pmRNSExercise of Options and Total Voting Rights
21st Aug 20237:00 amRNSNotice of interim results
17th Jul 20237:00 amRNSHalf-Year Trading Update
10th Jul 20237:00 amRNSDistribution agreement for OrthoPure® XT in the UK
25th May 20237:00 amRNSDistribution agreement with Australian Allografts
9th May 202312:00 pmRNSHolding(s) in Company
27th Apr 202312:35 pmRNSResult of AGM, Share Reorganisation &TVR
18th Apr 20237:00 amRNSProposed Share Reorganisation Timetable
5th Apr 20232:55 pmEQSHardman & Co Research on Tissue Regenix (TRX): Turning profitable and cash-generative
5th Apr 20237:00 amRNSCEO and CFO Share Purchases
30th Mar 20237:00 amRNSHolding(s) in Company
21st Mar 20237:00 amRNSFinal results for the year ended 31 December 2022
6th Mar 20237:00 amRNSNotice of results and Investor presentation
31st Jan 20237:01 amRNSTrading update for 2022
31st Jan 20237:00 amRNSChange of Adviser
18th Jan 202310:06 amRNSHolding(s) in Company
18th Jan 20237:00 amRNSChinese distribution agreement for OrthoPure® XT
7th Dec 20227:00 amRNSProduct launch in dCELL® division

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.